US · Healthcare · Biotechnology
EPS came in at -0.23 against a street estimate of -0.31 — a beat of 25.8%.
Analysts rate GH Research PLC a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $42.89.
| Fund | Stake |
|---|---|
| Lynx1 Capital Management, LP | 19.32% |
| Bvf Inc | 12.60% |
| RA Capital Management, LLC | 11.13% |
| FMR Inc | 8.71% |
| RTW INVESTMENTS, LLC | 8.64% |
| Deep Track Capital, LP | 4.86% |
| venBio Select Advisor LLC | 2.62% |
| Foresite Capital Management VI LLC | 1.37% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • GH Research PLC will present clinical-trial data from its GH001-TRD-201 and GH001-BD-202 trials. • The data will be | 2026-10-09 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • No financial results, operating metrics, or valuation information were provided in this filing. BUSINESS & SEGMENT HIGHLIGHTS • | 2026-09-11 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • GH Research reported a net loss of $15.146 million for the three months ended June 30, 2026, compared with $9.289 million in the s | 2026-08-06 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • GH Research PLC held its annual general meeting on June 25, 2026. • Shareholders passed all resolutions recommended by the board. | 2026-06-26 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • GH Research PLC announced on June 04, 2026, the full results from its Phase 2a trial of GH001 in postpartum depression (PPD). • T | 2026-06-04 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • GH Research PLC is an Ireland-based, clinical-stage biopharmaceutical company reporting under IFRS Accounting Standards issued by | 2026-03-05 |
| Annual report FY2024 (20-F) | 2025-02-27 |
| Annual report FY2023 (20-F) | 2024-03-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GH Research PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.